Two discovery disclosures landed this week: Boehringer Ingelheim reported novel cyclic GMP‑AMP synthase (cGAS) inhibitors aimed at autoinflammatory interferonopathies and fibrotic/metabolic lung diseases; Kymera Therapeutics published patents on STAT6 inhibitors with broad indications from oncology to autoimmune and metabolic disorders. Boehringer’s cGAS program targets an upstream innate immune sensor implicated in type I interferon responses—an approach with potential in rare autoinflammatory syndromes and chronic inflammatory organ disease. Kymera’s STAT6 patent filing signals continued interest in transcription‑factor modulation for immune and fibrotic indications, and positions the company to pursue targeted protein degradation or small‑molecule inhibitor strategies. Both disclosures underscore active industry investment in intracellular immune signaling nodes as drug targets; next steps will include selectivity, safety profiling, and biomarker strategies to define patient subsets most likely to benefit.